Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Organogenesis (ORGO : NSDQ)

• Company Description    Organogenesis is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. Number of Employees: 854

• Price / Volume Information    Yesterday's Closing Price: $1.71 Daily Weekly Monthly 20 Day Moving Average: 652,185 shares Shares Outstanding: 128.68 (millions) Market Capitalization: $220.03 (millions) Beta: 1.29 52 Week High: $7.08 52 Week Low: $1.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.06% -7.65% 12 Week -29.05% -30.56% Year To Date -66.99% -70.72%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 85 Dan Road - Canton,MA 02021 USA ph: 781-575-0775 fax: - organoir@westwicke.com http://www.organogenesis.com

• General Corporate Information    Officers Gary S. Gillheeney, Sr. - Chief Executive Officer; President and Chairman David Francisco - Chief Financial Officer Robert Ades - Director Michael J. Driscoll - Director Prathyusha Duraibabu - Director Peer Information Organogenesis (GSAC) Organogenesis (CASIF) Organogenesis (ALCD.) Organogenesis (OMNN) Organogenesis (CGPI.) Organogenesis (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 68621F102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 128.68 Most Recent Split Date: (:1) Beta: 1.29 Market Capitalization: $220.03 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.48 Price/Cash Flow: 2.64 Price / Sales: 0.48 EPS Growth vs. Year Ago Period: -688.89% vs. Previous Quarter: -91.89% Sales Growth vs. Year Ago Period: -56.68% vs. Previous Quarter: 17.53% ROE 06/30/26 - -23.89 03/31/26 - 9.63 12/31/25 - 21.41 ROA 06/30/26 - -11.13 03/31/26 - 4.76 12/31/25 - 10.84 Current Ratio 06/30/26 - 3.52 03/31/26 - 3.53 12/31/25 - 3.62 Quick Ratio 06/30/26 - 3.00 03/31/26 - 3.16 12/31/25 - 3.32 Operating Margin 06/30/26 - -12.38 03/31/26 - 4.83 12/31/25 - 9.78 Net Margin 06/30/26 - -19.94 03/31/26 - -0.84 12/31/25 - 5.32 Pre-Tax Margin 06/30/26 - -7.60 03/31/26 - 0.83 12/31/25 - 8.33 Book Value 06/30/26 - 1.15 03/31/26 - 1.90 12/31/25 - 2.36 Inventory Turnover 06/30/26 - 4.27 03/31/26 - 4.27 12/31/25 - 4.18 Debt-to-Equity 06/30/26 - 0.07 03/31/26 - 0.05 12/31/25 - 0.04 Debt-to-Capital 06/30/26 - 50.40 03/31/26 - 37.88 12/31/25 - 4.09

Powered by Zacks Investment Research ©